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Homocysteine in Myointimal Hyperplasia
M. Hansrani1, J. I. Gillespie2 and G. Stansby∗3
Departments of 1Surgery, 2Human Physiology and 3Vascular Surgery, University of Newcastle upon Tyne
Introduction: homocysteine, a sulphur-containing non-essential amino acid, appears to play a role in the pathophysiology
of atherosclerosis. However, its role in myointimal hyperplasia, the cause of almost 30% of failures of interventional
therapeutic procedures, is much less clear.
Methods: a review of the published scientific data concerning the role of homocysteine in myointimal hyperplasia was
performed using MEDLINE and other on-line databases. Evidence was sought from cell culture experiments, animal
models and clinical studies.
Results: several clinical studies have recently been published linking plasma homocysteine levels to restenosis in coronary
and peripheral arterial disease. However, several contradictory studies also exist making the role of homocysteine unclear.
There are currently no published randomised trials. Cell culture and animal model experiments have elucidated several
potential mechanisms by which may stimulate myointimal hyperplasia. Possible mechanisms include endothelial cell
activation with the enhanced release of inflammatory cytokines and growth factors and a direct effect on vascular smooth
muscle cell migration and proliferation.
Conclusion: further studies are required before the true role of homocysteine in the pathogenesis of myointimal hyperplasia
can be clearly evaluated. If evidence does confirm a role, the ease with which homocysteine levels can be normalised makes
it an attractive alternative therapeutic target for intervention.
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Introduction Myointimal Hyperplasia
Balloon angioplasty and surgical bypass techniques MIH can be considered an exaggerated healing re-
have revolutionised the management of patients with sponse to injury. Activated endothelial cells initiate
coronary and peripheral vascular disease. However, the inflammatory response via platelet activation, or
approximately a third of these patients will develop via the direct release of cytokines and growth hor-
restenosis1,2 mainly due to the development of myoin- mones. This leads to a cascade of effects which result
timal hyperplasia (MIH). Recently the non-essential in: migration of vascular smooth muscle cells (VSMC)
amino acid homocysteine (HCy) has been implicated from the media into the intima,8,9 VSMC proliferation
as a possible risk factor in premature graft and an- and phenotypic change to a more secretory fibroblastic
gioplasty restenosis.3–5 This has generated particular cell type10 and continued production of extracellular
interest as plasma levels of HCy can be normalised matrix (ECM), in particular collagen, in excess of de-
simply and cheaply by the intake of folic acid and the gradation;11 which eventually leads to stenosis of the
vitamins B6 and B12.6,7 However, the precise role of increasingly non-compliant vessel wall. Continued
HCy in the development of MIH remains unclear and trauma from the presence of sutures; shear stresses;12,13
will be the subject of this review. or low flow of blood in areas of turbulence perhaps
leading to a local concentration of harmful irritants in
the blood, may then act to maintain the endothelium
in an activated state. This leads to continuing platelet
∗ Please address all correspondence to: G. Stansby, Department of and macrophage activation even after the endothelialSurgery, University of Newcastle upon Tyne, Framlington Place,
Newcastle upon Tyne, NE2 4HH. monolayer has regenerated.
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At physiological concentrations HCy is able to inhibit
EC cell proliferation at the same time as stimulating
VSMC proliferation.26,27 Although, studies have also
shown increased EC turnover and aging in response
to elevated plasma HCy.24,28 HCy activates and dam-
ages endothelial cells by the generation of reactive
oxygen species29 combined with the removal of EC
Fig. 1. Structure of homocysteine. protective antioxidant mechanisms such as nitric
oxide (NO)30 and glutathione31 thus potentiating the
injurious effect and increasing activation. In VSMC
Homocysteine (see Figure 3) HCy stimulates proliferation through
a variety of means probably via a specific NMDA-like
HCy is a non-essential, non-protein forming, sul- receptor(s).32 These initiate several cellular cascades:
phur-containing amino acid, produced from the
• The induction of cyclin D1 and A in a dose-de-metabolism of dietary methionine (Fig. 1). The meta-
pendant manner stimulates the re-entry of thebolic pathways involving HCy are illustrated in Fig-
normally quiescent cells into the cell cycle26 viaure 2. It is found in the serum as protein-bound HCy
cyclin-dependant kinase,33(70%), HCy-HCy and HCy-Cysteine mixed di-
• Activation of phospholipases such as C and D,sulphides (30%) or as free HCy thiolactone (1%).
the synthesis of diacylglycerol (DAG) and inositolElevations of plasma total HCy have a multi-factorial
triphosphate (IP3) leads to an increase in intra-basis, resulting from a combination of increased diet-
cellular calcium ions and activation of proteinary intake of methionine, inheritable genetic defects
kinase C (PKC). Both of these intermediaries areand vitamin deficiencies (Fig. 2).14 Severe homo-
capable of activating mitogen activating proteincysteinaemia (>100 mol/l) results from rare
(MAP) kinase which leads to activation of DNAhomozygous genetic defects such as deficiency
transcription factors and cellular proliferation,22,32of cystathionine  synthase (CS), methylene-
• Redox-specific and dose-dependant PKC ac-tetrahydrofolate reductase (MTHFR) or of enzymes
tivation leads to transcription of c-myb and c-fosinvolved in methyl-B12 synthesis and homocysteine mRNA which code for proteins that combine withmethylation. Mild (15–30 mol/l) to moderate
others to form AP-1 which in turn initiates tran-(30–100 mol/l) homocysteinaemia is due to vitamin
scription of genes involved in cellular pro-deficiencies, heterozygous CS defect, or MTHFR
liferation,34thermolability. These later genetic defects have been
• Potentiation of the mitogenic effect of angiotensinfound to affect a third of some populations, whilst
II35 and possibly other growth factors.vitamin deficiencies play a large role in the elevated
levels of HCy found in the elderly population.15–17 HCy directly inhibits the production and extra-
cellular release of specific proteins. This stimulatesFree HCy and HCy-th are highly reactive
molecules, forming non-covalent and covalent bonds a decrease in the release of heparin-like compounds,
which are potent inhibitors of VSMC proliferation,36with a variety of molecules, in particular cysteine-
rich or other thiol moieties.18,19 This can lead to loss as well as producing a highly procoagulant milieu
through the modulation of elements of the co-of electrical charge, conformational changes or even
precipitation of the protein, resulting in loss or de- agulation and fibrinolytic pathways.37–40 The co-
agulation/fibrinolytic pathways are furthergradation of the biological function of multiple en-
zymes, receptors, growth factors and structural modulated through chemical interactions with other
cysteine moieties present in the protein structure ofproteins.20,21 HCy is also known to activate and in-
activate specific mRNA transcription and stimulate many proteins involved in these pathways. HCy is
in addition able to modulate the activity of matrixDNA synthesis directly perhaps via a specific re-
ceptor, which initiates calcium fluxes in an as yet metalloproteinases (MMPs) and their inhibitors
(TIMPs) leading to elastin degradation and ac-unclear mechanism.22,23
The role of the endothelial cell (EC) is central to cumulation of collagen within the intima and media
in a dose-dependant manner.41,42the aetiology of MIH.24 Endothelial cells have a lower
basal intracellular HCy concentration and appear to Recent studies have shown that, in vitro and in vivo,
HCy has a direct effect on vasodilatation selectivelybe more influenced by extracellular concentrations of
the amino-acid, suggesting an increased sensitivity/ inhibiting endothelium-dependant vasodilatation,
predominantly through inhibition of NO.43,44decreased ability to metabolise it than other cells.25
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Fig. 2. Homocysteine metabolism in man. Key: MS=methionine synthase, MTHFR=methylene tetrahydrofolate reductase, CS=
cystathionine  synthase, GNMT=glycine N-methyltransferase.
Fig. 3. Mechanisms by which cellular proliferation may be induced by homocysteine in vascular smooth cells.
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Homocysteine and Clinical Restenosis and unlikely to be due to MIH. Benoit50 in a prospective
trial of 222 patients undergoing coronary angioplasty
An association between elevated blood levels of homo- in France who were followed up clinically for 6 months,
found no significant differences in homocysteine levelscysteine (HCy) and cardiovascular disease was ori-
ginally postulated in 1969.45 Thirty percent of patients between patients with multiple restenosis (n=79; diag-
nosed by coronary angiography in 55 cases, by myo-presenting to vascular clinics have elevated plasma
HCy, compared to 2–5% in the normal population.46 cardial scintigraphy in 23 cases and strongly suspected
clinically in one patient) or those requiring re-There has been a deluge of studies assessing HCy as
a risk factor for cardiovascular disease in the last 10 vascularisation, and those without restenosis and not
requiring revascularisation. Morita et al.51 con-years. Boushey et al.47 published a meta-analysis of 27
studies to 1995, looking at almost 4000 patients. They secutively enrolled 112 male patients who had under-
gone a successful elective coronary artery angioplastyfound that HCy was an independent, graded risk
factor for atherosclerotic disease in coronary, cerebral and measured plasma HCy at follow-up angiography
(3–6 months). They found that HCy levels were sig-and peripheral vessels. They calculated the odds ratio
of a 5 mol/l increment of plasma HCy level for nificantly higher (15.0 vs 13.0 mol/l) in patients with
restenosis (final stenosis >50% more than 3 monthscoronary artery disease (CAD) of 1.6, cerebrovascular
disease (CVA) of 1.5 and for peripheral vascular disease post angioplasty). Finally, HCy was found to be sig-
nificantly higher (23.6±7.8 versus 16.9±7.1 mol/l)(PVD) of 6.8 although this value is likely to be in-
accurate due to the small number of trials involving in a case–control study of heart transplant patients who
developed graft vasculopathy, defined as coronaryPVD available for analysis. These results have been
supported by a further 40 subsequent studies48 and stenosis >25% or aneurysms, as opposed to those who
did not.52 Blood was sampled a mean of 52 weeks postwill not be considered further here. The evidence for
the role of HCy in premature restenosis post thera- transplant.
peutic revascularisation by vein graft or angioplasty
is, in comparison, much less clear. However, studies
Homocysteine and restenosis in peripheral vasculardo exist in both coronary and peripheral vascular
diseasedisease and will be reviewed. There are currently no
published studies of the association between plasma
Irvine3 in a retrospective case-control study of 19HCy and restenosis in cerebrovascular disease.
patients (median age 70 years at intervention) who
had undergone infrainguinal vein bypass grafting and
had developed stenosis between 6 weeks and 1 year
post-operatively (defined as angiographically de-Homocysteine and coronary restenosis
termined lumen reduction of >50% or with a persistent
duplex abnormality (minimum of 2 scans) with aIwama4 in a study of 40 patients who had undergone
saphenous vein coronary artery bypass grafting doubling of velocities) matched against similar
patients (n=19) who had not, found plasma HCy to(CABG) 1–13 years (mean 6.1±3.1 years) previously,
found that patients with MIH (n=23) in any graft be significantly elevated in those who later developed
stenoses (median 17.8 mol/l vs 13.8 mol/l). Mires-(defined as angiographic stenosis [50%) had sig-
nificantly elevated plasma HCy levels (median 15.1 vs kandari5 performed a similar study prospectively in 62
limbs (median age 72 years) undergoing femorodistal10.6 mol/l) compared to those with no evidence of
restenosis. Using multiple regression analysis they vein bypass. They confirmed that elevated plasma
HCy was a risk factor for restenosis at 12 monthswere able to show that elevated HCy appeared to be
an independent risk factor for vein graft stenosis. (median 14.4 mol/l, range 9.6–32 vs 9.5 mol/l).
However, they do not state whether or not they ex-However, this retrospective study may be misleading
as it supposes that levels of HCy remain relatively cluded stenoses occurring within the first 6 weeks.
Interestingly, Beattie et al.53 found hyper-unchanged over several years, which is as yet un-
established. Eritsland,49 in a prospective cohort study homocysteinaemia (>12.2 mol/l in women and
>15.5 mol/l in men) in 57% of 57 patients undergoingof 565 patients undergoing CABG in Norway found
no such association between the preoperative HCy infrainguinal vein bypass surgery. Nonetheless they
found that plasma HCy levels were not associatedlevels and the frequency of graft occlusions (de-
termined by angiography) at 1-year. Unfortunately with restenosis/outcome directly in these patients, but
that it was significantly associated with the de-they did not exclude stenoses occurring within the
first 6 weeks, which are usually due to thrombosis velopment of pre-existing MIH in the vein and this,
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Table 1. Therapeutic options in hyperhomocysteinaemia.in turn, was associated with an increased risk of graft
failure. Tsakiris et al.54 also found no correlation be- • Lifestyle changes
• Folic acidtween HCy levels and rates of restenosis in 71 patients
• Pyroxidine (B6)(age 68±13 years) undergoing percutaneous an-
• Vitamin B12gioplasty of predominantly femoropopliteal segments • Betaine
• Vitamin C/Vitamin Eof artery in patients with PVD (52% of whom had
elevated HCy levels). Currie55 reviewed 66 patients
selected retrospectively and correlated HCy levels with
Monkeys fed an ‘‘atherogenic diet’’ developed im-failure of vascular intervention, which they defined
paired EC-dependent vasodilatation in resistance ves-as, return of symptoms with a fall in ankle-brachial
sels of the lower limb44 and defects in the protein Cpressure index, requirement for further re-
anticoagulant pathway.61 These atherosclerotic hy-vascularisation procedure in the same limb or am-
perhomocysteinaemic monkeys when fed vitamin Bputation. Using multiple logistic regression they found
supplemented atherosclerotic diet for 6 months dem-hyperhomocysteinaemia to be an independent risk
onstrated a significant fall in plasma HCy levelsfactor for the failure of all forms of peripheral vascular
(12.8±2.8 to 3.5±0.3 mol/l), though this did notintervention, including angioplasty, endarterectomy
normalise vascular function or prevent progression ofand bypass grafting, along with young age at inter-
structural lesions. This may be due to the fact thatvention and diabetes.
the elevation in HCy caused by the diet was small,Unfortunately, these studies do not as yet give us a
however, it is more likely that this lack of effect wasclear picture of the strength of the link between el-
due to the persistent hypercholesterolaemia inducedevated HCy levels and MIH. Differences in the timing
by the atherosclerotic diet, which was not affected byof blood taken for HCy levels, the length of time to
the vitamin supplementation. Zulli et al.62 dem-follow-up, differences in outcomes assessed, possible
onstrated a synergistic effect of the combination ofpublication biases and the relatively small number of
diet-induced hyperhomocysteinaemia and hyper-studies overall mean no definitive conclusions can be
cholesterolaemia in rats as measured by aortic wallreached.
thickness and disintegration of the elastic lamina when
compared against the effects of feeding with each
agent alone.
Hyperhomocysteinaemia also induced procoagulantRestenosis in animal models of hyperhomocysteinaemia
effects,63,64 increased prostaglandin synthesis,65 in-
creased diapedesis through mesenteric post capillaryA number of mammals have been used as models for
venules66 and increased cyclin-dependant kinase inthe effects of elevated HCy in man. Baboons con-
rats.33tinuously infused with HCy developed sustained aor-
Although these studies demonstrate that HCy cantic EC loss and regeneration, platelet consumption and
initiate or maintain endothelial and vessel wall injury,intimal lesion formation typical of arteriosclerotic or
there is at present only one study looking specificallypreatherosclerotic intimal lesions composed of pro-
at MIH in animals: Southern et al.67 studied the effectsliferating VSMC surrounded by collagen, elastin fibres,
of HCy on restenosis in carotid endarterectomisedglycosaminoglycans and sometimes lipid.24 Similar
rats. They found a 4-fold increase in MIH in thehistological changes have been reproduced in rats,56
diet-induced hyperhomocysteinaemic group (36.32±minipigs57 and rabbits58 fed methionine-rich diets.
15.28 mol/l) when calculated as percent lumen steno-Matthias further demonstrated the potentiation of
sis and a 8-fold increase in MIH area when comparedHCy-induced damage by other atherogenic substances
to normals. Using a linear regression model to comparesuch as cholesterol, angiotensin II, cholestane, cholic
HCy levels and percent stenosis they were able toacid and methylthiouracil in spontaneously hyper-
demonstrate a linear relationship between the two.tensive rats. Young59 found an increase in mal-
ondialdehyde, a major secondary oxidation product
of polyunsaturated lipids, in nitrous oxide-induced
hyperhomocysteinaemic pigs, whilst increased Therapeutic Options in Hyperhomocysteinaemia
(Table 1)markers of lipid peroxidation were also noted in hy-
perhomocystaemic rabbits.58 However, plasma HCy
To date, therapeutic attempts at preventing MIH havelevels were far in excess of that usually found in
hyperhomocysteinaemic patients and in fact, in vivo been unsatisfactory. Homocysteine provides a par-
ticularly attractive therapeutic target as blood levelslipid peroxidation has not been demonstrated in man.60
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can be easily normalised with the administration of effective treatment could potentially have wide ap-
plications in both coronary and peripheral vascularcheap, patient-acceptable, oral vitamin treatment. The
implementation of a ‘‘cardiovascular lifestyle’’ is par- disease. HCy, if proven to be a true primary risk factor,
would be an attractive target for therapy since it isticularly apt, with decreased red meat intake, increased
fruit and fibre, low coffee consumption, smoking ces- both easily measured and easily treated. To date the
majority of epidemiological studies have confirmedsation and regular exercise which have all been shown
to decrease plasma HCy levels.68 Both Brattstrom et al.6 that elevated levels of HCy are associated with PVD,
though the association with the development of MIHand Clarke et al.69 in reviews of randomised controlled
trials of the effects of folic acid±pyridoxine and B12 is still tenuous. Animal and in vitro studies have
demonstrated potential mechanisms by which HCyadministration on lowering plasma HCy levels, found
that combined vitamin treatment could significantly could produce endothelial injury, smooth muscle cell
activation and other aspects of the pathophysiologyreduce plasma HCy levels. Among these vitamins
folic acid had the most potent effect: the higher the of MIH, and support the hypothesis that it is an
important risk factor for MIH. Though few prospectivepretreatment plasma HCy and the lower the pre-
treatment plasma folic acid level the greater the effect. studies and no randomised trials of HCy lowering
therapy have yet been published. Such studies areIn vitro and in vivo studies have demonstrated em-
pirical reduction in HCy-induced EC damage, VSMC needed before therapy to lower HCy can be widely
recommended.proliferation and inhibition of vasodilatation when
any of these vitamins were added.70–72 There are cur-
rently no defined guidelines as to the recommended
doses of these vitamins, or the level of HCy at which
treatment should be initiated.6,68 Wilcken et al.73 have
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